What happened with ICLR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Drug developers need evidence that a treatment is safe and effective. Icon Plc helps design trials, organize physicians and research sites, recruit patients and manage studies worldwide. Its Accellacare research network supports patient recruitment. The company also provides related consulting and services after products reach the market. Pharmaceutical, biotechnology and medical-device companies pay for this work, alongside government and public-health organizations.
Clients generally agree to a fixed contract price, sometimes with variable components. They typically pay part of the fee when a trial starts and the rest in installments, sometimes tied to milestones. Contracts can run for several years, so revenue depends on studies starting and continuing, not simply on winning new work.
The business depends on clients continuing to fund and outsource research, and on recruiting suitable patients and investigators. Key customers supply a substantial share of revenue, but no single customer dominates. Clients can delay or cancel studies as results, funding or priorities change. ICON must also follow local clinical-trial rules and laws governing patient data; regulators can halt research, reject trial data or restrict data processing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ICON depends on pharmaceutical and biotechnology sponsors’ clinical-development spending, with Parexel and Syneos Health also competing for that work despite being absent from this list.
IQVIA competes with ICON to run outsourced clinical-development programs for pharmaceutical and biotechnology companies. Its Research & Development Solutions business is the part to watch for competition over those customers’ spending.
Fortrea competes with ICON for drug sponsors’ spending on managing Phase I–IV trials, regulatory advice and post-approval evidence studies. Its Clinical Services revenue is a useful read on this overlapping work, with leading pharmaceutical customers accounting for 56% of its fiscal 2025 revenue.
Medpace and ICON both earn fees from pharmaceutical, biotechnology and medical-device companies for full-service Phase I–IV clinical development. Medpace’s work with small and mid-sized biopharmaceutical customers is worth watching for demand in a customer group ICON also serves.
Thermo Fisher’s PPD business competes directly with ICON to run large clinical-development programs for pharmaceutical and biotechnology customers. Watch PPD rather than Thermo Fisher’s overall results, which also include extensive laboratory-product businesses.
Charles River and ICON both depend on pharmaceutical and biotechnology customers’ drug-development budgets: Charles River handles drug discovery and non-clinical safety testing, while ICON runs clinical trials. Charles River’s Discovery and Safety Assessment revenue shows spending on the stages before clinical trials.
Medpace Holdings, Inc. earningsMEDP
Medpace’s report will show whether small and mid-sized biopharma customers are still funding trials, a customer group that also hires ICON.
Look for demand in Medpace’s clinical-development work and signs of new projects. Steady demand and more work would suggest these sponsors still have funds to outsource trials, supporting ICON’s opportunity to win similar work. Weakening demand would point to tighter budgets that could mean fewer awards or pressure on ICON’s fees.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s PPD business competes with ICON for large trial programs, so its report will show how sponsors’ outsourcing demand and competition are shaping that work.
Focus on PPD’s clinical-development work, not Thermo Fisher’s laboratory-products business. Steady PPD demand and project profitability would suggest large drugmakers are still outsourcing trials at fees that cover delivery costs. Weaker activity or squeezed profitability would point to tougher competition for ICON’s large programs or pressure on fees.
Icon Plc earningsThis company
ICON earns fees by running clinical trials, and its report will show whether revenue from project work is covering delivery costs and protecting margins.
Read revenue growth alongside operating margin, the share of revenue left after operating costs. Rising revenue with a steady margin suggests work is progressing into recognized revenue without delivery costs outrunning fees. Slower revenue or a falling margin points to delays, cancellations, or cost overruns squeezing the economics of ICON’s projects.
IQVIA Holdings Inc. earningsIQV
IQVIA’s Research & Development Solutions competes with ICON for clinical-development work, and its report will show how sponsor demand and pricing are affecting that market.
Read IQVIA’s Research & Development Solutions revenue alongside its profitability. Both holding up would suggest sponsors are still buying outsourced development and competition is not sharply eroding project economics, supporting ICON’s ability to win work and defend fees. Weakening revenue or profitability would point to demand or competitive pressure on ICON’s opportunities and margins.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate matters to ICON because a higher rate can raise interest paid on its variable-rate debt, while a lower rate can reduce that expense.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can increase interest expense on ICON’s variable-rate term loan and revolving facility, leaving less operating cash for other needs.
If it comes in below expectations
Lower rates can reduce interest expense on ICON’s variable-rate term loan and revolving facility, leaving more operating cash for other needs.
Charles River Laboratories International, Inc. earningsCRL
Charles River’s discovery and safety-testing work comes before clinical trials, so its report will show whether drug developers are funding work that may later feed ICON’s trial pipeline.
Look at revenue and demand in Charles River’s Discovery and Safety Assessment business. Steady activity would suggest drugmakers are still funding preclinical work, leaving more potential programs to advance into the clinical trials ICON runs. A downturn would point to a thinner future pool of work for ICON.
